JP2016517883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517883A5 JP2016517883A5 JP2016511718A JP2016511718A JP2016517883A5 JP 2016517883 A5 JP2016517883 A5 JP 2016517883A5 JP 2016511718 A JP2016511718 A JP 2016511718A JP 2016511718 A JP2016511718 A JP 2016511718A JP 2016517883 A5 JP2016517883 A5 JP 2016517883A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- composition according
- subject
- sovetirom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 7
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 206010008129 cerebral palsy Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000004669 very long chain fatty acids Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819467P | 2013-05-03 | 2013-05-03 | |
| US61/819,467 | 2013-05-03 | ||
| PCT/US2013/053640 WO2014178892A1 (en) | 2013-05-03 | 2013-08-05 | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018137754A Division JP2018162321A (ja) | 2013-05-03 | 2018-07-23 | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016517883A JP2016517883A (ja) | 2016-06-20 |
| JP2016517883A5 true JP2016517883A5 (enExample) | 2016-09-23 |
Family
ID=51843844
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016511718A Withdrawn JP2016517883A (ja) | 2013-05-03 | 2013-08-05 | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
| JP2016511726A Active JP6360552B6 (ja) | 2013-05-03 | 2014-02-05 | 髄鞘形成疾患の処置におけるソベチロム |
| JP2018118891A Pending JP2018141024A (ja) | 2013-05-03 | 2018-06-22 | 髄鞘形成疾患の処置におけるソベチロム |
| JP2018137754A Pending JP2018162321A (ja) | 2013-05-03 | 2018-07-23 | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016511726A Active JP6360552B6 (ja) | 2013-05-03 | 2014-02-05 | 髄鞘形成疾患の処置におけるソベチロム |
| JP2018118891A Pending JP2018141024A (ja) | 2013-05-03 | 2018-06-22 | 髄鞘形成疾患の処置におけるソベチロム |
| JP2018137754A Pending JP2018162321A (ja) | 2013-05-03 | 2018-07-23 | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10226438B2 (enExample) |
| EP (1) | EP2991670B8 (enExample) |
| JP (4) | JP2016517883A (enExample) |
| CN (1) | CN105431163A (enExample) |
| AU (1) | AU2014260468A1 (enExample) |
| BR (1) | BR112015027682A2 (enExample) |
| CA (1) | CA2911309A1 (enExample) |
| ES (1) | ES2745532T3 (enExample) |
| MX (2) | MX379043B (enExample) |
| RU (1) | RU2015151216A (enExample) |
| SG (2) | SG11201509012QA (enExample) |
| WO (2) | WO2014178892A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| CA3035502A1 (en) | 2014-04-30 | 2015-11-05 | Kannan Rangaramanujam | Dendrimer compositions and their use in treatment of diseases of the eye |
| WO2016025741A1 (en) | 2014-08-13 | 2016-02-18 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| JP7088473B2 (ja) * | 2015-10-29 | 2022-06-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 |
| WO2017185083A1 (en) * | 2016-04-22 | 2017-10-26 | Viking Therapeutics | Use of thyroid beta-agonists |
| WO2017185087A1 (en) | 2016-04-22 | 2017-10-26 | Viking Therapeutics | Use of thyroid beta-agonists |
| DK3457851T3 (da) * | 2016-05-18 | 2021-09-20 | Univ Oregon Health & Science | Derivater af sobetirom |
| KR102537274B1 (ko) * | 2016-08-12 | 2023-05-25 | 오레곤 헬스 앤드 사이언스 유니버시티 | 아마이드 화합물, 이의 약학 조성물 및 이들을 이용하는 방법 |
| WO2018183940A1 (en) * | 2017-03-31 | 2018-10-04 | Neurovia, Inc. | Methods and compositions for treating niemann-pick disease |
| WO2018201007A2 (en) | 2017-04-27 | 2018-11-01 | The Johns Hopkins University | Dendrimer compositions for use in angiography |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US10780069B2 (en) * | 2017-05-18 | 2020-09-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of GC-1 in transplant related population |
| EP3644983B1 (en) | 2017-06-29 | 2023-10-25 | Yale University | Compositions and methods of treating or preventing fibrotic lung diseases |
| CN110891583B (zh) | 2017-07-18 | 2023-06-06 | 学校法人庆应义塾 | 针对Th1细胞诱导性细菌的抗菌组合物 |
| CA3082121C (en) | 2017-11-10 | 2023-01-24 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| WO2020123861A1 (en) | 2018-12-12 | 2020-06-18 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| CN113784950A (zh) | 2019-03-01 | 2021-12-10 | 速通医疗公司 | 新型拟甲状腺素药 |
| AU2020391467A1 (en) | 2019-11-29 | 2022-06-23 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| JP7759322B2 (ja) | 2019-12-04 | 2025-10-23 | アシュバッタ セラピューティクス， インコーポレイテッド | 眼に薬物送達するためのデンドリマー組成物および方法 |
| CN111116684B (zh) * | 2019-12-31 | 2020-09-25 | 厦门甘宝利生物医药有限公司 | 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物 |
| EP4168384A4 (en) | 2020-06-17 | 2024-07-10 | Autobahn Therapeutics, Inc. | THYROMIMETICS |
| EP4167986A4 (en) | 2020-06-17 | 2024-11-20 | Autobahn Therapeutics, Inc. | THYROMIMETICS |
| WO2023081458A1 (en) * | 2021-11-08 | 2023-05-11 | Rutgers, The State University Of New Jersey | Systems and methods for diagnosis and/or treating demyelinating neuropathy |
| CN115569233B (zh) * | 2022-10-17 | 2023-07-14 | 湖南大学 | 既能吸光又能与自由基反应的高效光抑制剂的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| DE69636677D1 (de) | 1995-12-13 | 2006-12-14 | Univ California | Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors |
| CA2260992C (en) | 1996-08-20 | 2004-03-09 | The Regents Of The University Of California | Eye treatments using synthetic thyroid hormone compositions |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| JP2002519340A (ja) | 1998-06-30 | 2002-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 甲状腺ホルモン類似体およびそれらの調製方法 |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7302347B2 (en) | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
| JP2007505837A (ja) * | 2003-09-15 | 2007-03-15 | オードウェイ リサーチ インスティテュート | 甲状腺ホルモンアナログおよび新脈管形成における使用の方法 |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| WO2006012015A2 (en) | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| AU2005284879B2 (en) | 2004-09-15 | 2011-04-14 | Albany College Of Pharmacy And Health Sciences | Thyroid hormone analogs for promoting angiogenesis |
| US20090117054A1 (en) | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| SG178002A1 (en) * | 2006-10-20 | 2012-02-28 | Biogen Idec Inc | Treatment of demyelinating disorders |
| CA2704279C (en) * | 2006-11-03 | 2014-09-30 | University Of Saskatchewan | Method of treating demyelination diseases |
| FI20075245A0 (fi) * | 2007-04-11 | 2007-04-11 | Markku Ahotupa | Menetelmä oksidatiivisen metabolian arvioimiseksi |
| PT2187882E (pt) | 2007-07-11 | 2013-04-17 | Medicinova Inc | Tratamento de uma doença neurodegenerativa progressiva com ibudilast |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| BRPI0910850B1 (pt) | 2008-04-21 | 2022-06-14 | Otonomy, Inc. | Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva |
| CN102612363A (zh) | 2009-05-20 | 2012-07-25 | 舌交付有限公司 | 口腔和/或舌下治疗制剂 |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| EP2651357B1 (en) | 2010-12-16 | 2020-04-01 | Sunovion Pharmaceuticals Inc. | Sublingual films |
| BR112015009313B1 (pt) * | 2012-10-25 | 2021-03-23 | Volvo Truck Corporation | Sistema de freio pneumático controlado eletronicamente para um veículo automotivo, veículo automotivo equipado com um tal sistema e método para controle de um tal sistema |
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
-
2013
- 2013-08-05 WO PCT/US2013/053640 patent/WO2014178892A1/en not_active Ceased
- 2013-08-05 JP JP2016511718A patent/JP2016517883A/ja not_active Withdrawn
-
2014
- 2014-02-05 JP JP2016511726A patent/JP6360552B6/ja active Active
- 2014-02-05 MX MX2015015228A patent/MX379043B/es unknown
- 2014-02-05 RU RU2015151216A patent/RU2015151216A/ru not_active Application Discontinuation
- 2014-02-05 WO PCT/US2014/014943 patent/WO2014178931A1/en not_active Ceased
- 2014-02-05 AU AU2014260468A patent/AU2014260468A1/en not_active Abandoned
- 2014-02-05 SG SG11201509012QA patent/SG11201509012QA/en unknown
- 2014-02-05 CA CA2911309A patent/CA2911309A1/en not_active Abandoned
- 2014-02-05 US US14/888,577 patent/US10226438B2/en active Active
- 2014-02-05 BR BR112015027682A patent/BR112015027682A2/pt not_active IP Right Cessation
- 2014-02-05 EP EP14791718.1A patent/EP2991670B8/en active Active
- 2014-02-05 CN CN201480038129.XA patent/CN105431163A/zh active Pending
- 2014-02-05 SG SG10201709090UA patent/SG10201709090UA/en unknown
- 2014-02-05 ES ES14791718T patent/ES2745532T3/es active Active
-
2015
- 2015-10-30 MX MX2021000538A patent/MX2021000538A/es unknown
-
2018
- 2018-06-22 JP JP2018118891A patent/JP2018141024A/ja active Pending
- 2018-07-23 JP JP2018137754A patent/JP2018162321A/ja active Pending
-
2019
- 2019-02-13 US US16/275,117 patent/US20190175531A1/en not_active Abandoned
-
2020
- 2020-07-07 US US16/922,852 patent/US11510887B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015025228A3 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| NZ707640A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| JP2015528471A5 (enExample) | ||
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| JP2015523407A5 (enExample) | ||
| ME02179B (me) | Metoda za lečenje atrijalne fibrilacije | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| TN2012000458A1 (en) | Uses of dgat1 inhibitors | |
| PH12012502447A1 (en) | Tetrahydrocarboline derivative | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| BR112012029170A2 (pt) | fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2016539157A5 (enExample) | ||
| WO2016142708A3 (en) | Pharmaceutical composition | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| JP2017505809A5 (enExample) | ||
| JP2016069317A5 (ja) | 腎不全進行抑制剤、腎不全予防剤、尿毒症治療剤、インドキシル硫酸産生阻害剤、心血管系疾患予防剤、及び食品組成物 | |
| MX2013002649A (es) | Agente terapeutico contra el dolor. | |
| BR112012021445A2 (pt) | formulação farmacêutica ou neutracêutica. | |
| JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
| EP4574150A3 (en) | A magl inhibitor | |
| NZ602807A (en) | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor |